ASCO 2024 | Identifying optimal patient subgroups in ovarian cancer for neoadjuvant PARP inhibitor therapy

Stephanie Lheureux • 1 Jun 2024

ASCO 2024

NEO

Stephanie Lheureux, MD, PhD, University of Toronto, Toronto, Canada, discusses identifying patient subgroups in ovarian cancer likely to benefit from neoadjuvant PARP inhibitor therapy. Initially, the NEO trial (NCT02489006) relied on clinical criteria for patient selection. The current focus includes integrating biomarkers such as breast cancer gene (BRCA) and homologous recombination deficiency (HRD) status into clinical trials to enhance patient stratification. Functional assays, including the olaparib window of opportunity, are proposed to assess HRD status more effectively. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria – AstraZeneca; GlaxoSmithKline; Merck; Roche/Genentech; Seagen; Shattuck Labs
Consulting or Advisory Role – AstraZeneca; GlaxoSmithKline; Merck; Novartis; Roche/Genentech; Shattuck Labs
Research Funding – AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst)